Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
RBC Capital analyst Douglas Miehm maintains Knight Therapeutics (TSX:GUD) with a Outperform and raises the price target from...
RBC Capital analyst Douglas Miehm maintains Knight Therapeutics (TSX:GUD) with a Outperform and lowers the price target from...
MONTREAL, Oct.
Knight Therapeutics Inc. (TSX: GUD) (OTC: KHTRF)
Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) announced today that its Colombian affiliate, Biotoscana Farma S...
- Invasive candidiasis is an infection caused by a yeast (a type of fungus) called Candida. and is a serious infection that can...
Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, today announce...
Knight Therapeutics Inc. (TSX:GUD), ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced toda...
